ClinicalTrials.gg
RecruitingNCT04465474Updated Feb 8, 2024

Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)

An observational study in COVID-19, sponsored by Chinese University of Hong Kong. Recruiting at 10 sites in 3 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Chinese University of Hong Kong · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
3,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in COVID-19 by Chinese University of Hong Kong — 3 open to participants now, 8 under way, none of them phase 3. COVID-19 · Chinese University of Hong Kong.

Planned enrollment
Largest of 15
3,000 · median 200
Started
2020
with 6 others
Observational
15 of 21
2 open now
Registered
6th of 21
by date

Among the 21 studies in COVID-19 by Chinese University of Hong Kong, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2020, is one of 15 observational ones, and was the 6th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 21 studies in COVID-19 by Chinese University of Hong Kong are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in COVID-19 by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.

Read the detailed description

With over 10 million individuals infected worldwide, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health crisis. It is recognized that pregnant women are at an increased risk of acquiring viral respiratory infection and developing severe pneumonia due to the physiologic changes in their immune and cardiopulmonary systems. Previous studies have attempted to determine maternal and perinatal outcome and potential risk of vertical transmission in pregnant women affected by COVID-19, however, relevant clinical data and biological samples have not been collected in a systematic manner. The research project will engage in collaborative research across obstetricians/maternal-fetal medicine subspecialists, gynecologist, infectious disease specialists, pediatrician, developmental and molecular biologists and bioinformatician between the CUHK, China and Spain. The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.

Results generated will inform obstetrics and gynecology, pediatric and infectious disease scientific communities as well as public health specialists and policy makers regarding: (1) the estimated seroconversion rate in women of childbearing age; these results will help (i) improve the approach to care for pregnancy and childbirth during the COVID-19 outbreak; and (ii) formulate preventive measures to be implemented specifically for pregnant women in reducing risk of infection and associated complications to both the women and their unborn child; (2) the impact of COVID-19 on maternal and perinatal outcomes; data from high-quality research will inform practice during the COVID-19 outbreak, guiding healthcare professionals on how to adjust the management approach to infected pregnant women and the exact risks the infection poses to the babies; (3) the risk of vertical transmission at different stages of pregnancy and its sequelae; findings of this study will guide counselling, decision making and clinical management; (4) the identification of cellular site of viral entry and replication in the maternal-fetal interface that would be instrumental in designing therapeutic measures to cease vertical transmission and developing therapeutic treatments.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • pregnancy
  • vertical transmission
  • pregnancy loss
  • ACE2 TMPRSS2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant women

Eligibility criteria

Objective 1: Seroconversion during pregnancy

Inclusion criteria:

  • Pregnant women who attended for Down syndrome screening (DSS) at 11-13 weeks
  • Had serum sample taken between 1 November 2019 and 1 June 2020 consented for stored serum for future research
  • Intended to deliver at the booking hospital.

Objective 2: SARS-CoV-2 and pregnancy loss

Inclusion criteria:

•Pregnant women presenting with first and second trimester miscarriage in Hong Kong and Spain, as well as those with stillbirth during periods of 6 and 12 months, respectively.

Objective 3: Pregnancy course and perinatal outcome

Inclusion criteria:

•Pregnant women affected by COVID-19

Objective 4: Vertical transmission

Inclusion criteria:

•Pregnant women affected by COVID-19

Objective 5: Potential mechanisms for vertical transmission

Inclusion criteria:

•Pregnant women affected by COVID-19

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
3,000 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • OtherNon Intervention

    It's an observational study, no intervention involves.

06

What researchers measure

Primary outcomes

  1. Seroconversion during pregnancy - DSS1

    Mother

    Time frame: At DSS1 (Around 11-13 weeks gestation)

  2. Seroconversion during pregnancy - At delivery

    Mother

    Time frame: At Delivery

  3. Pregnancy loss

    Mother (1st); Mother and abortus/stillborn baby(2nd)

    Time frame: At pregnancy loss

  4. Pregnancy course and perinatal outcome

    Mother and Baby

    Time frame: From date of recruited until the date of delivery

  5. Vertical transmission

    Mother and Baby

    Time frame: At Newborn 0 hours of life, mother immediately after delivery

  6. Vertical transmission

    Mother and Baby

    Time frame: At Newborn 7 days of life

  7. Vertical transmission

    Mother and Baby

    Time frame: At Newborn 14 days of life

  8. Vertical transmission

    Mother and Baby

    Time frame: At Newborn 6 months of life

  9. Vertical transmission

    Mother and Baby

    Time frame: At Newborn 18 months of life

  10. Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection.

    Mother and Baby

    Time frame: through study completion, up to 2 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Apr 2024, 47 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 47 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2020
First posted
Jul 10, 2020
StartActual
May 1, 2020
Primary completionEst.
Apr 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04465474
Collaborators
Peking University First Hospital, Hospital Universitario de Torrejón, Queen Mary Hospital, Hong Kong, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, Hong Kong, United Christian Hospital, Kwong Wah Hospital, Princess Margaret Hospital, Hong Kong, Tuen Mun Hospital
Responsible party
Chiu Yee Liona Poon (Prof Poon, Chiu Yee Liona, Chinese University of Hong Kong) — Principal investigator
First posted
Jul 10, 2020
Start date
May 1, 2020
Primary completion
Apr 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Feb 8, 2024

Study contacts

Liona POON
Contact
liona.poon@cuhk.edu.hk
(852) 3505 2582
Equal CHEN
Contact
equalchen@cuhk.edu.hk
(852) 3505 1536

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion